Atlas Trials

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

Clinical trial NCT02895906 · COMPLETED

Trial details

NCT number
NCT02895906
Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
22q11.2 Deletion Syndrome
Start date
2016-11-28
Primary completion
2017-04-13
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.